📸 It is time for you to be a part of it: Share your #myESMOStory at #ESMO25. 🤳Find our selfie spots across the Congress venue and snap a photo—alone or with your team. 🔗 https://t.co/hgLbflWOhG

Landmark practice-changing readout delivered by #Charlesgayer, shifting SOC. DESTINY-Breast05, Ph. III, shows T-DXd beating T-DM1 post-neoadjuvant in high-risk HER2+ eBC (IDFS HR 0.47 95% CI 0.34-0.66, p <0.001). #ESMO25 #BreastCancer @myESMO @OncLive @OncoAlert @DanaFarber

💥 anti-TIGIT fails again (I can’t remember how many times I have posted negative results of these agents) 🏙️ Tiragolumab + atezolizumab did not improve PFS versus durvalumab in unresectable stage III NSCLC after chemoradiation in SKYSCRAPER-03 trial. #LCSM #ESMO25

📢 Huge day at #ESMO25! The Presidential Session delivered multiple clinical practice-changing studies that will redefine standards of care across oncology. 🔬👏 Grateful to witness innovation turning into impact. @myESMO

#StefanoPartelli on #ASPEN trial results in #PanNETs <2cm at @myESMO #ESMO25 Important prospective study that confirms that #surgery is #NOT requiered is small tumours We had been waiting long for this 👏🏻👏🏻 Congrats for the effort😊 @GrupoGetne @ENETS_ORG #ESMOAmbassadors

#ESMO25 Day 2 ✅ Another day of impactful science and meaningful exchanges at the Congress. Browse today’s news and expert insights in the #ESMODailyReporter 📌 https://t.co/WIKr2GumZw

@stolaney1 cautions to follow the trial data for #DB05 Should not use T-DXd in ALL HER-2 + #bcsm with residual disease- only those that met trial entry..really unresectable large size or node positive #ESMO25 #ESMOAmbassadors

Here we are, part of the members of our @myESMO #CommunicationCommittee Thanks for everything you do the whole year! 🙌🏻 #ESMO25

#ESMO25: New evidence presented for #ADCs moving into the curative setting in #BreastCancer and #BladderCancer. @PTarantinoMD discusses the ‘unleashing’ of neoadjuvant and adjuvant ADC therapy to reduce recurrence and save lives #ESMODailyReporter ➡️ https://t.co/VEQtPvywZL

4th and final Practice-relevant win presidential for today by #NicolettaColombo. ENGOT-ov65/KEYNOTE-B96: pembro + weekly paclitaxel +/- bev improves PFS (8.3 vs 6.4 mo; HR 0.70) in platinum-resistant ovarian cancer and OS benefit in PD-L1 CPS≥1 (HR 0.76). #ESMO25 #OvarianCancer

#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter ➡️ https://t.co/GVIEH3Dd0u #immunotherapy @RKristeleit

KEYNOTE-905 #ESMO25 Presidential #GU #MIBC - very different population to #BreastCancer! but will more MIBC patients now become Cis-ineligible? Interesting to me as a #breastcancer doc that MIBC patients accept to be randomized to EVP vs no treatment? #ESMOambassadors @OncoAlert

ADCs are transforming outcomes in the curative setting —across cancer types. We just saw the outstanding results of DB-11, DB-05, KN-905. It’s only the beginning. For a deep dive into this evolving field, here’s my latest editorial on ESMO Daily Reporter: https://t.co/DSwIYC2QJL

#ChristofVulsteke presents awaited results of neoadj #EVpembro for cisplatin ineligible #bladdercancer. Improves EFS w HR 0.4, improves OS w HR 0.5 compared to cystectomy. New periop tx for our pts. @myESMO #ESMO25 #ESMOAmbassadors @OncoAlert

Field-moving data , a new-era, with #Christofvulsteke in cisplatin-ineligible MIBC. KEYNOTE-905, Ph.III, finds periop EV+pembro smashing risk (EFS HR 0.40), improving survival (OS HR 0.50), and quadrupling pCR to 57% vs 9%. #ESMO25 #BladderCancer @myESMO @Annals_Oncology

Bladder cancer #ESMO25 in 1 slide. #goosebumps #newSOCnow #micdrop #standingovation Neoadjuvant EVP = New SOC MIBC Cis-ineligible!

Post-neoadj tx similar and T-DM1 varied by 🌎 region 💡 ILD 🫁 LOW- 4.4% T-DXd vs. 5.1% AC-THP Dose reductions in T-DXd arm 1/3 that of standard arm Discontinuations 🟰 #ESMO25 #ESMOAmbassadors

Ok, with more T-DXd (than the 4 cycles in #DB11) our ILD rates go ⬆️ 🫁 ILD- 9.6% vs 1.6% w/ T-DM1 and we see 2 deaths Discontinuation of T-DXd 17.9% vs. 12.9% T-DM1 #ESMO25 #ESMOAmbassadors

DB-11 neoadj TDX-d for ⬆️ risk (node + or >5cm) HER-2+ #bcsm ‼️TDXd mono closed🚪 early, so T-DXd X4 -> THP vs. ddAC-> THP 90% node ➕ PCR ⬆️ 11.2% ( 9.1% HR+, 16.1% HR-) RCB 0/1 also ⬆️ 12.2% (13.3% HR+, 9.2% HR-) #ESMO25 #ESMOAmbassadors

@JavierCortesMD asks the pertinent questions... These new ADCs have efficacy, but studies are missing the key SOC ADCs that are already present in many countries 🌎 . 🏔️Challenge to approval and to interpret results globally. #ESMO25 #ESMOAmbassadors

Planned final survival analysis from FLAURA2 @NEJM after #ESMO25 presentation. Pts with #EGFR mutant NSCLC randomized to osimertinib + chemo had improved OS vs osi alone (47.5m vs 37.6m, OS HR 0.77). AEs leading to d/c was 12% vs 7%. #ESMOAmbassadors https://t.co/SB80xzQfZ9